Your session is about to expire
← Back to Search
Light Therapy
Low-Level Light Therapy for Dry Eye Syndrome (ELOM Trial)
N/A
Waitlist Available
Led By Eric R Ritchey, OD, PhD
Research Sponsored by University of Houston
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 3 weeks
Awards & highlights
ELOM Trial Summary
This trial will investigate how light therapy affects the glands in the eyes that produce oil and if it can help treat dry eye disease. Participants will receive 3 15-min sessions of light therapy & meibum samples will be taken before/after.
Eligible Conditions
- Meibomian Gland Dysfunction
- Dry Eye Syndrome
ELOM Trial Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 3 weeks
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~3 weeks
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Meibum protein composition
Secondary outcome measures
Meibum lipid composition
Other outcome measures
Non-invasive tear break up time
Tear lipid layer thickness
Tear meniscus height
ELOM Trial Design
1Treatment groups
Experimental Treatment
Group I: Low-Level Light TherapyExperimental Treatment1 Intervention
All subjects will receive 3 15-minute treatments of low level light therapy
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Red Low-Level Light Therapy
2023
N/A
~30
Find a Location
Who is running the clinical trial?
University of HoustonLead Sponsor
147 Previous Clinical Trials
47,522 Total Patients Enrolled
University of LouisvilleOTHER
338 Previous Clinical Trials
75,954 Total Patients Enrolled
Eric R Ritchey, OD, PhDPrincipal InvestigatorThe University of Houston College of Optometry
1 Previous Clinical Trials
20 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:Research Study Groups:
This trial has the following groups:- Group 1: Low-Level Light Therapy
Awards:
This trial has 1 awards, including:- No Placebo-Only Group - All patients enrolled in this study will receive some form of active treatment.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Meibomian Gland Dysfunction Patient Testimony for trial: Trial Name: NCT05859295 — N/A
Frequently Asked Questions
These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
Are any participants still needed for this research endeavor?
"According to the details present on clinicaltrials.gov, this particular medical trial has concluded its recruitment process and is no longer accepting participants. It was first posted on May 12th 2023 with a final update being made five days later. There are nevertheless 46 other trials in active progress at the moment that are recruiting patients."
Answered by AI
Who else is applying?
What state do they live in?
Texas
What site did they apply to?
The University of Houston College of Optometry
What portion of applicants met pre-screening criteria?
Did not meet criteria
How many prior treatments have patients received?
1
Why did patients apply to this trial?
As I age more vision problems. Concerned TBI is. contributing to new occurrences..
PatientReceived 2+ prior treatments
What questions have other patients asked about this trial?
How is medicine administered? Since college program are trial patients paid?
PatientReceived 2+ prior treatments
Other Trials to Consider
Popular Categories
Share this study with friends
Copy Link
Messenger